- Home
- APLM vs QNTM Comparison
APLM vs QNTM Comparison
Compare APLM & QNTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- QNTM
- Stock Information
- Founded
- APLM 2016
- QNTM 1998
- Country
- APLM United States
- QNTM Canada
- Employees
- APLM N/A
- QNTM N/A
- Industry
- APLM Blank Checks
- QNTM
- Sector
- APLM Finance
- QNTM
- Exchange
- APLM Nasdaq
- QNTM NYSE
- Market Cap
- APLM 7.7M
- QNTM 8.7M
- IPO Year
- APLM N/A
- QNTM N/A
- Fundamental
- Price
- APLM $6.16
- QNTM $7.28
- Analyst Decision
- APLM Strong Buy
- QNTM
- Analyst Count
- APLM 2
- QNTM 0
- Target Price
- APLM $425.00
- QNTM N/A
- AVG Volume (30 Days)
- APLM 42.6K
- QNTM 1.5M
- Earning Date
- APLM 04-15-2025
- QNTM 05-13-2025
- Dividend Yield
- APLM N/A
- QNTM N/A
- EPS Growth
- APLM N/A
- QNTM N/A
- EPS
- APLM N/A
- QNTM N/A
- Revenue
- APLM $2,101,000.00
- QNTM N/A
- Revenue This Year
- APLM N/A
- QNTM N/A
- Revenue Next Year
- APLM N/A
- QNTM N/A
- P/E Ratio
- APLM N/A
- QNTM N/A
- Revenue Growth
- APLM 70.54
- QNTM N/A
- 52 Week Low
- APLM $6.20
- QNTM $2.70
- 52 Week High
- APLM $63.00
- QNTM $44.20
- Technical
- Relative Strength Index (RSI)
- APLM 42.37
- QNTM 55.07
- Support Level
- APLM $6.50
- QNTM $6.45
- Resistance Level
- APLM $8.00
- QNTM $8.36
- Average True Range (ATR)
- APLM 1.36
- QNTM 1.47
- MACD
- APLM -0.22
- QNTM 0.16
- Stochastic Oscillator
- APLM 5.93
- QNTM 29.30
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.